Applying different cancer cell lines, Murai et al. observed that enzymatic PARP inhibition is sufficient for synergistic effects by combination therapy with TOP-1 Inhibitors (see above), while PARP trapping is necessary for alkylating agents such as temozolomide [58]. Here, PARP1 is linked to cancer.